In conclusion, our study confirms that radiomics features based on baseline MRI can help early and accurately predict tumor shrinkage patterns after NAC in HR+/HER2- breast cancer patients, who generally have a lower response rate to NAC. The gene discussed is ERBB2; the disease is breast cancer.